Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2016 - 2020
Net Income	-1.92	-1	-0.64	-0.12	0	-0	Upgrade
Stock-Based Compensation	-	-	0.07	0.07	-	-	Upgrade
Change in Accounts Receivable	-0	-0.03	0.01	0.01	-	-	Upgrade
Change in Accounts Payable	0.39	0.1	0.23	0.03	0	-	Upgrade
Change in Other Net Operating Assets	-0.03	0	0.01	0.01	-0	-0	Upgrade
Operating Cash Flow	-1.54	-0.93	-0.33	-0.01	0	-0.01	Upgrade
Short-Term Debt Issued	-	-	-	-	0	-	Upgrade
Total Debt Issued	-	-	-	-	0	-	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	0	-	Upgrade
Issuance of Common Stock	1.65	0.75	0.5	-	-	-	Upgrade
Financing Cash Flow	1.65	0.75	0.5	-	0	-	Upgrade
Net Cash Flow	0.07	-0.17	0.17	-0.01	0	-0.01	Upgrade
Cash Interest Paid	-	-	0.01	0.01	0	0	Upgrade
Levered Free Cash Flow	-0.85	-0.55	-	0.03	0	-0.01	Upgrade
Unlevered Free Cash Flow	-0.85	-0.55	-	0.03	0	-0	Upgrade
Change in Net Working Capital	-0.35	-0.07	-	-0.03	-0	0	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.